Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsMunetoshi ANDO, Keiko GOTO
Life of this patent
Estimating the term…
Loading patent…
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsMunetoshi ANDO, Keiko GOTO
Estimating the term…
The invention provides a method for treating a cancer with a human FOLR1-targeting drug by increasing an expression of folate receptor α (hereinafter abbreviated to FOLR1) by using an antagonist for folic acid metabolism, a medicament for a cancer containing a human FOLR1-targeting drug for increasing an expression of FOLR1 by using an antagonist for folic acid metabolism and a method for enhancing a therapeutic effect of a human FOLR1-targeting drug by increasing an expression of FOLR1 in a cancer cell by using an antagonist for folic acid metabolism. For example, the invention provides a more effective therapeutic method using an antagonist for folic acid metabolism with a human FOLR1-targeting drug, for cancer patients in which an expression level of FOLR1 is low and in which an anti-tumor activity of the human FOLR1-targeting drug is not exhibited sufficiently or for cancer patients in which a treatment of a cancer expressing FOLR1 is to be further enhanced.
A method for treating a cancer by using a human FOLR1-targeting drug, wherein an expression of folate receptor α (hereinafter abbreviated to FOLR1) is increased by using an antagonist for folic acid metabolism.
A method for enhancing a therapeutic effect of a human FOLR1-targeting drug by increasing an expression of FOLR1 in a cancer cell by using an antagonist for folic acid metabolism.
A medicament for a cancer containing a human FOLR1-targeting drug for increasing an expression of FOLR1 in a cancer cell by administering an antagonist for folic acid metabolism.
Dependencies are inferred from the claim text.